• 3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test.
• 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from antigen to molecular without the need for expensive and complex equipment, high-cost consumables, or long-term contracts.

3EO Health, a “Point of Life” diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published a new market price of $14.95 per test.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327647032/en/

3EO high efficiency molecular 3TR technology enables testing to be executed in multiple settings and locations. 3EO's sample-to-test workflow eliminates the need for mixing, pipetting, or technique dependent manual steps. With a cost per test up to 70% lower than existing technologies, 3EO is seeking to create access to molecular technology for more physicians and consumers by providing molecular POC tests under $15. (Graphic: Business Wire)

3EO’s proprietary 3TR technology was developed to enable molecular performance at never-before-seen price points across a number of clinical domains to include respiratory and sexually transmitted infections. 3EO Health received EUA authorization for its COVID-19 test utilizing 3TR technology in Q4 of 2023. With the help of its U.S. suppliers and supply chain partners, 3EO is now excited to be the first to offer point-of-care molecular testing for under $15 per test.

“Constituents in U.S. healthcare are constantly feeling the tension between cost and quality,” said Jeremy Schubert M.B.A, M.P.H., Chief Executive Officer of 3EO Health. “Although molecular technologies are more sensitive, antigen testing still dominates the point of care market. Despite the perfusion of new technologies, none have sufficiently reduced the cost or complexity to enable clinicians to overcome this tension and make the move to molecular. We are excited to be the first to simultaneously remove both barriers.”

At $14.95 per test, 3EO costs up to 70% less than existing technologies. 3EO is currently running programs with key distributor partners for instrument acquisition and on-going utilization that lower costs even further. Physicians should check with one of 3EO’s authorized distributors for details.

For more information about 3EO Health and its 3TR Technology, please visit 3EOhealth.com.

About 3EO

3EO Health Inc. is a “Point of Life” diagnostic company leveraging novel technology to exponentially lower cost and expand clinical and community access to high impact diagnostic tools. Our passion is to create a world where every person is empowered to optimize health - for their patients, communities, family, and self. We seek to ensure physicians and consumers have equitable access to the best technology that is both affordable and easy to use. We enable people to thrive by extending the four walls of the health system into the community, work, and home. Our mantra is “… the right information, in the right place, at the right time, enabling the right action, right now.” For more information visit 3EOhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327647032/en/